

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6499220

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALCON INC.	06/23/2020
RECEIVING PARTY DATA	
Name:	NOVARTIS AG
Street Address:	LICHTSTRASSE 35
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12401168
Application Number:	13352009
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8627785892
Email:	maria.johnson@novartis.com, pip_inbox.phchbs@novartis.com
Correspondent Name:	MARIA G. JOHNSON
Address Line 1:	ONE HEALTH PLAZA
Address Line 2:	NOVARTIS PHARMACEUTICAL CORPORATION
Address Line 4:	EAST HANOVER, NEW JERSEY 07936
ATTORNEY DOCKET NUMBER:	PAT903483-US
NAME OF SUBMITTER:	MARIA G. JOHNSON
SIGNATURE:	/Maria G. Johnson/
DATE SIGNED:	01/15/2021
Total Attachments: 13	
source=PAT903483-ALCONtoNAGwithANNEX#page1.tif	
source=PAT903483-ALCONtoNAGwithANNEX#page2.tif	
source=PAT903483-ALCONtoNAGwithANNEX#page3.tif	
source=PAT903483-ALCONtoNAGwithANNEX#page4.tif	

source=PAT903483-ALCONtoNAGwithANNEX#page5.tif
source=PAT903483-ALCONtoNAGwithANNEX#page6.tif
source=PAT903483-ALCONtoNAGwithANNEX#page7.tif
source=PAT903483-ALCONtoNAGwithANNEX#page8.tif
source=PAT903483-ALCONtoNAGwithANNEX#page9.tif
source=PAT903483-ALCONtoNAGwithANNEX#page10.tif
source=PAT903483-ALCONtoNAGwithANNEX#page11.tif
source=PAT903483-ALCONtoNAGwithANNEX#page12.tif
source=PAT903483-ALCONtoNAGwithANNEX#page13.tif

2 June 2020

ALCON INC.

NOVARTIS AG

**THIRD INTELLECTUAL PROPERTY
ASSIGNMENT AGREEMENT**

CONTENTS

CLAUSE	PAGE
1. ASSIGNMENT.....	1
2. TRANSFER PROCEDURE	2
3. NO WARRANTIES.....	3
4. NOTICES.....	3
5. MISCELLANEOUS PROVISIONS.....	4
6. DISPUTE RESOLUTION	5
SCHEDULE 1 DEFINITIONS AND INTERPRETATION	8
EXHIBIT 1 ADDITIONAL ASSIGNED IP RIGHTS	

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

dated May 25, 2020

PARTIES:

- (1) **ALCON INC.**, a corporation (Aktiengesellschaft) incorporated in the Canton of Fribourg, Switzerland with enterprise identification number (UID) CHE-234.781.164 and its registered office at Rue Louis-d’Affry 6, 1701 Fribourg, Switzerland (the *Assignor* or *Alcon*); and
- (2) **NOVARTIS AG** a corporation (Aktiengesellschaft) incorporated in the Canton of Baselstadt, Switzerland with enterprise identification number (UID) CHE-103.867.266 and its registered office at Lichtstrasse 35, 4056 Basel, Switzerland (the *Assignee* or *Novartis*);

together, the *Parties*, and each a *Party*.

Words and expressions used in this Agreement shall be interpreted in accordance with Schedule 1 (*Definitions and Interpretation*).

Whereas:

- (A) Novartis and Alcon have entered into a Separation and Distribution Agreement dated 8 April 2019, under which: (a) Novartis agreed to transfer, or procure the transfer of, certain assets and license certain Intellectual Property Rights to Alcon; and (b) Alcon has agreed to transfer, or procure the transfer of, certain assets and license certain Intellectual Property Rights to Novartis (the *Separation Agreement*).
- (B) Pursuant to the Separation Agreement, the Parties entered into an Intellectual Property Assignment dated 8 April 2019 (the First Intellectual Property Assignment Agreement) to effectuate the assignment of the Assigned Intellectual Property (as defined in the First Intellectual Property Assignment Agreement) from Novartis or its Affiliates to Alcon.
- (C) The Additional Assigned IP Rights were inadvertently included in the Assigned Intellectual Property.
- (D) Pursuant to Clause 25 (Wrong Pockets) of the Separation Agreement, the Assignor now wishes to convey, transfer and assign (or procure that the relevant Affiliate of the Assignor conveys, transfers and assigns) its (or its relevant Affiliate’s) right, title and interest in and to the Additional Assigned IP Rights to the Assignee, and the Assignee wishes to acquire from the Assignor (or the relevant Affiliate of the Assignor) such right, title and interest.

IT IS AGREED:

1. ASSIGNMENT

1.1 Assignment. Pursuant to the Separation Agreement, and subject to Clauses 1.2 (*Third Party Agreements*) and 1.4 (*License back to the Assignor of Assigned Patents*), and in consideration of the mutual exchange of promises in this Agreement, the sufficiency of which are agreed and acknowledged, each Assignor hereby conveys, transfers and assigns (or procures that the relevant Affiliate of that Assignor hereby conveys, transfers and assigns) to the

Assignee, and the Assignee hereby accepts the conveyance, transfer and assignment of, all of each Assignor's (or the relevant Assignor Affiliate's) right, title, and interest in and to the Assigned Intellectual Property, including the right to:

- (a) sue (and to retain damages recovered) in respect of any infringement or unauthorised use of any of the Assigned Intellectual Property that may have occurred before the Effective Date; and
- (b) initiate any other action, suit or proceeding before all Governmental Entities with respect to the Assigned Intellectual Property.

1.2 **Effective Date.** The assignment under Clause 1.1 (Assignment) shall be effective on 8 April 2019 to the extent permitted under Applicable Laws and, in all other cases, shall be effective as of the date of this Agreement (as applicable, the **Effective Date**).

1.3 **Third Party Agreements.** The rights transferred to the Assignee under Clause 1.1 (Assignment) shall be limited by, and subject to, any rights granted by Assignor and/or its Affiliates to any Third Party before the Effective Date in relation to the Additional Assigned IP Rights.

1.4 **License back to the Assignor of Assigned Intellectual Property.** With effect from the Effective Date, the Assignee hereby grants to each Assignor and its Affiliates a license to use the Additional Assigned IP Rights on the terms of the relevant Patent and Know-How Licence and/or relevant Brand Licence, in each case as applicable, at no additional cost to the Assignor (or its Affiliates).

2. TRANSFER PROCEDURE

2.1 **Recordals.** Except as otherwise agreed by the Parties, the Assignee shall be responsible for:

- (a) preparing and filing all documentation necessary for the purposes of recording the transfer of the Assigned Intellectual Property from the Assignor (or its Affiliate) to the Assignee, with any relevant intellectual property office or authority (the **Recordals**); and
- (b) all filing fees and expenses associated with the Recordals.

2.2 **Further assurances.** Subject to Clause 2.3 (*Limitations to further assurance obligations*), the relevant Assignor shall, at the cost and reasonable request of the Assignee

execute and deliver (or procure the execution and delivery of) any further documents that may be reasonably required for the purposes of the Recordals.

2.3 **Limitations to further assurance obligations.**

- (a) The Parties agree that Clauses 2.3(b) and 2.4 shall apply to the extent that an Assignor is prevented from complying with its further assurance obligations under Clause 2.2 in respect of any Assigned Intellectual Property as a result of:
 - (i) Applicable Law;
 - (ii) the Assignor's internal sanctions and export control policy, or anti-bribery and corruption policy, in each case, as in force from time to time; or

(iii) any other factor beyond the reasonable control of the Assignor,

(each such affected Assigned Intellectual Property Right being an *Affected Right* and each of (i) to (iii) being a *Restriction* and together, *Restrictions*).

(b) Each Assignor shall notify the Assignee, as soon as reasonably practicable, after becoming aware of any Affected Right or Restriction, of:

(i) each Affected Right and the territory in which it is registered (or is the subject of an application to register); and

(ii) the relevant Restriction.

2.4 As soon as reasonably practicable following the Assignee's receipt of the notice referred to in Clause 2.3(b), Alcon and Novartis shall discuss in good faith the means by which the Assignee may be able to achieve a protection which is equivalent or similar to the protection provided by the Affected Right and the allocation of the associated costs between the Parties; and in light of the limitations imposed by the Restrictions, Alcon and Novartis will use reasonable efforts to achieve the agreed means.

3. NO WARRANTIES

ALL REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS OF ANY KIND, WHETHER EXPRESS OR IMPLIED (BY STATUTE OR OTHERWISE), REGARDING THE ASSIGNED INTELLECTUAL PROPERTY OR RELATING TO THE TERMS AND CONDITIONS OR THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING ANY REPRESENTATION, WARRANTY OR UNDERTAKING OF SUITABILITY, FITNESS FOR PURPOSE OR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS) ARE EXPRESSLY EXCLUDED TO THE MAXIMUM EXTENT PERMITTED BY LAW. THE ASSIGNEE IS SOLELY RESPONSIBLE FOR ITS USE, RELIANCE ON OR IMPLEMENTATION OF THE ASSIGNED INTELLECTUAL PROPERTY, INCLUDING ANY ACTIONS OR DECISIONS TAKEN OR NOT TAKEN AS A RESULT THEREOF.

4. NOTICES

4.1 Form of notice. Any notice to be given in connection with this Agreement shall be in writing in English and signed by or on behalf of the Party giving it (in the case of notice by e-mail, a notice signed electronically or a scanned copy of a signed original notice shall suffice). It shall be delivered by hand, registered post, e-mail or courier using an internationally recognised courier company. Any notice to Assignee shall be deemed notice to all members of Novartis Group, and any notice to Alcon shall be deemed notice to all members of Alcon Group.

4.2 Effectiveness of notice. A notice shall be effective upon receipt and shall be deemed to have been received at the time of delivery, if delivered by hand, registered post or courier, or at the time of transmission if delivered by e-mail (subject to confirmation or evidence of receipt). Where delivery occurs outside Working Hours, notice shall be deemed to have been received at the start of Working Hours on the next following Business Day.

4.3 Notice details. The addresses and e-mail addresses of the Parties for the purpose of Clause 4.1 (*Form of notice*) are:

Alcon and each member of the Alcon Group	For the attention of: General Counsel
---	---------------------------------------

	Alcon Inc. Rue Louis-d' Affry 6, 1701 Fribourg, Switzerland royce.bedward@alcon.com
--	--

Novartis and each member of the Novartis Group	For the attention of: Head Legal M&A (Novartis International AG) Novartis AG Lichtstrasse 35, 4056 Basel, Switzerland jonathan.emery@novartis.com
---	--

4.4 Change of notice details. Licensee and Licensor shall each notify the other Party in writing of a change to its details in Clause 4.1 (*Form of notice*) from time to time.

5. MISCELLANEOUS PROVISIONS

5.1 Waivers, Rights and Remedies. Except as expressly provided in this Agreement, no failure or delay by any Party in exercising any right or remedy relating to this Agreement shall affect or operate as a waiver or variation of that right or remedy or preclude its exercise at any subsequent time. No single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any other remedy.

5.2 No Third Party Enforcement Rights. A Person who is not a Party to this Agreement shall have no right under any statutory provision to enforce any of its terms.

5.3 Counterparts. This Agreement may be executed in any number of counterparts, and by each Party on separate counterparts. Each counterpart is an original, but all counterparts shall together constitute one and the same instrument. Delivery of a counterpart of this Agreement by e-mail attachment shall be an effective mode of delivery.

5.4 Variations. No amendment of this Agreement shall be valid unless it is in writing and duly executed by or on behalf of all of the Parties to it.

5.5 Invalidity. Each of the provisions of this Agreement is severable. If any such provision is held to be or becomes invalid or unenforceable in any respect under the law of any jurisdiction, it shall have no effect in that respect and the Parties shall use Commercially Reasonable Efforts to replace it in that respect with a valid and enforceable substitute provision the effect of which is as close to its intended effect as possible.

5.6 Whole Agreement.

(a) This Agreement and the other Transaction Documents together set out the whole agreement between the Parties in respect of the subject matter of this Agreement and supersedes any previous draft, agreement, arrangement or understanding, whether in writing or not, relating to its subject matter. It is agreed that:

- (i) no Party has relied on or shall have any claim or remedy arising under or in connection with any statement, representation, warranty or undertaking made by or on behalf of the other Party (or any of its Representatives) in relation to the subject matter of this Agreement that is not expressly set out in this Agreement and the other Transaction Documents;
 - (ii) any terms or conditions implied by Applicable Law in any jurisdiction in relation to the subject matter of this Agreement are excluded to the fullest extent permitted by Applicable Law or, if incapable of exclusion, any rights or remedies in relation to them are irrevocably waived;
 - (iii) the only right or remedy of a Party in relation to any provision of this Agreement shall be for breach of this Agreement; and
 - (iv) except for any liability in respect of a breach of this Agreement, neither Party (nor any of its Representatives) shall owe any duty of care or have any liability in tort or otherwise to the other Party (or its respective Representatives in relation to the subject matter of this Agreement).
- (b) Nothing in this Clause 5.6 (*Whole Agreement*) shall limit any liability for (or remedy in respect of) fraud or fraudulent misrepresentation.
- (c) Each Party agrees to the terms of this Clause (*Whole Agreement*) on its own behalf and as agent for each of its Representatives.

5.7 Governing Law. This Agreement and any non-contractual obligations arising out of or in connection with this Agreement shall be governed by, and interpreted in accordance with, the substantive laws of Switzerland (excluding its rules on conflict of laws and excluding the UN Convention on Contracts for the International Sale of Goods).

6. DISPUTE RESOLUTION

6.1 This Clause 6 (*Dispute Resolution*) shall apply to any dispute, controversy or claim arising out of or relating to this Agreement, including a dispute, controversy or claim relating to the existence, validity or termination of this Agreement (each, a *Dispute*).

6.2 Before entering into any arbitration pursuant to Clauses 6.4 or 6.4(a), Alcon (on its own behalf or on behalf of any member of the Alcon Group) or Novartis shall give written notice of a Dispute to the other (a *Dispute Notice*). The Dispute Notice shall:

- (a) state that it is a Dispute Notice being submitted pursuant to this Clause 6 (*Dispute Resolution*);
- (b) identify the Dispute in sufficient detail to allow the Party receiving the Dispute Notice to understand reasonably the nature of the Dispute; and
- (c) set out any steps taken by that Party or its Affiliates to resolve it.

6.3

- (a) Upon receipt of a Dispute Notice, each of Novartis and Alcon shall refer the Dispute to its Group General Counsel (or, if they are not reasonably available during the relevant period, their appointed alternate, who shall be of sufficient seniority within the relevant Party and have authority to be able to reach a resolution of the Dispute) and the two

Group General Counsel shall attempt in good faith to settle the Dispute by means of an appropriate written agreement setting out the terms on which the Dispute is resolved within twenty (20) Business Days of the date of receipt of the Dispute Notice (the **Resolution Period**). The time limit specified in this Clause 6.3 may be extended by the written agreement of the Parties.

- (b) Notwithstanding the foregoing, either Party may, at any time, seek interim or provisional relief, whether from an emergency arbitrator appointed and acting in accordance with the LCIA Rules, a tribunal constituted under the LCIA Rules and/or from a national court of competent jurisdiction, in advance of or in aid of the arbitration proceedings contemplated by Clause 6.4.

6.4 If Novartis and Alcon do not conclude a binding written agreement settling the Dispute within the Resolution Period, either Party shall be entitled to refer the Dispute to be finally resolved by arbitration. In those circumstances, the Parties agree that:

- (a) the arbitration shall be conducted in accordance with the LCIA Arbitration Rules in effect at the date of this Agreement (the **LCIA Rules**);
- (b) the tribunal shall comprise three arbitrators, with one arbitrator selected by each Party and the chairperson selected by the LCIA Court. The chairperson shall not be of Swiss or American nationality;
- (c) the seat of arbitration shall be London;
- (d) the written and spoken language to be used in the arbitral proceedings shall be English; and
- (e) the award of the arbitral tribunal shall be final and binding upon the parties and judgment may be entered on an award in any court of competent jurisdiction.

6.5 Where the Dispute relates to or is in any way connected with any dispute referred to arbitration under any other Ancillary Agreement, either Novartis or Alcon may apply to the LCIA Court at any time before the tribunal is fully constituted in either arbitration requesting that the two arbitrations be consolidated and the Parties hereby agree that in such circumstances the arbitrations are to be consolidated by the LCIA Court. In the event of consolidation, the Parties agree that the consolidated arbitration shall be conducted under the LCIA Rules in accordance with Clause 6.4.

6.6 Novartis and Alcon agree that any settlement discussions and communications or negotiations in connection with the proposed resolution of a Dispute are without prejudice to the Parties' positions, are to be kept confidential, and shall not be used or submitted in any arbitration or other legal proceeding between the Parties for any purpose. For the avoidance of doubt, this Clause 6.6 shall not affect a Party's right to submit and rely on any correspondence marked "without prejudice save as to costs" for the purpose of the tribunal's determination on costs.

Signature Page Follows Schedules and Exhibits

SCHEDULE 1

DEFINITIONS AND INTERPRETATION

1. **Definitions.** In this Agreement, the following words and expressions shall have the following meanings:

Additional Assigned IP Rights means the utility patents and applications listed in Exhibit 1 together with any patents or applications that claim rights of priority to the listed patents or applications or any patents or applications to which priority is claimed by the patents and applications listed in Exhibit 1.

Affected Right has the meaning given in Clause 2.3(a);

Affiliate has the meaning given in the Separation Agreement;

Agreement means this intellectual property assignment agreement;

Alcon Group has the meaning given in the Separation Agreement;

Applicable Law has the meaning given in the Separation Agreement;

(a)

Business Day means a day, other than a Saturday or Sunday or public holiday in Switzerland or the United States, on which banks are open in Basel, Fribourg, Geneva, Zurich and New York City for general commercial business;

Commercially Reasonable Efforts has the meaning given in the Separation Agreement;

Dispute has the meaning given in Clause 6.1;

Dispute Notice has the meaning given in Clause 6.2;

Effective Date means the date of this Agreement;

Governmental Entity has the meaning given in the Separation Agreement;

Intellectual Property Rights means all (i) Patents; (ii) Know-How; (iii) Trademarks; (iv) Internet domain names; and (v) works of authorship, copyrights, database rights, mask work rights and registrations and applications therefor;

LCIA Rules has the meaning given in Clause 6.4(a);

Novartis Group has the meaning given in the Separation Agreement;

Patent and Know-how License Agreement has the meaning given in the Separation Agreement;

Patents means, whether domestic or foreign, any patent applications and issued patents;

Person means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, unincorporated organisation, Governmental Entity or other entity;

Product List has the meaning given to it in the Separation Agreement;

Records has the meaning given in Clause 2.1(a);

Representatives has the meaning given in the Separation Agreement;

Resolution Period has the meaning given in Clause 6.3;

Restriction and **Restrictions** has the meaning given in Clause 2.3(a);

Separation Agreement has the meaning given in the Recitals;

Third Party means a Person other than the Assignor, the Assignee or their respective Affiliates from time to time;

Third Party Agreements has the meaning given in Clause 1.2 (*Third Party Agreements*);

Transaction Document has the meaning given in the Separation Agreement; and

Working Hours means 9.00am to 5.00pm in the relevant location on a Business Day.

2. **Definitions.** In this Agreement, unless the context otherwise requires:

- (a) headings do not affect the interpretation of this Agreement; the singular shall include the plural and vice versa; and references to one gender include all genders;
- (b) references to any English legal term or concept shall, in respect of any jurisdiction other than England, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction; and
- (c) any phrase introduced by the terms **including**, **include**, **in particular** or any similar expression shall be construed as without limitation and illustrative and shall not limit the sense of the words preceding those terms.

3. **Enactments.** Except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any jurisdiction) includes references to (i) that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii) any enactment which that enactment re-enacts (with or without modification); and (iii) any subordinate legislation (including regulations) made (before or after the date of this Agreement) under that enactment, as amended, consolidated or re-enacted as described in (i) or (ii) above, except to the extent that any of the matters referred to in (i) to (iii) occurs after the date of this Agreement and increases or alters the liability of Novartis or Alcon (or any Person on whose behalf it is acting as agent pursuant to this Agreement) under this Agreement.

4. **Schedules and Exhibits.** The Schedules and Exhibits comprise schedules and exhibits to this Agreement and form part of this Agreement.

5. **Inconsistencies.** Where there is any inconsistency between the definitions set out in Schedule 1 (*Definitions and Interpretation*) and the definitions set out in any Clause or any other Schedule or Exhibit, then, for the purposes of construing such Clause or Schedule or Exhibit, the definitions set out in such Clause, or Schedule or Exhibit (as applicable) shall prevail.

Exhibit 1
Additional Assigned IP Rights

Patents:
As appended (Patent Family PAT903483)

Domain Names:



extravan.org

SIGNATURE

This Agreement is signed by duly authorised representatives of the Parties:

NOVARTIS AG

Executed this 3 day of June 2020


_____

Name: Ian James Hiscock
Authorized Signatory



Name: Aisa Harbin
Authorized Signatory

Title: _____

Title: _____

ALCON INC.

Executed this 25 day of June 2020


_____

Name: Christine Bohmann

Name: PATRICK RYAN

Title: Authorized Signatory

Title: AUTHORIZED SIGNATORY

CASE REFERENCE	COUNTRY	FILING NUMBER	FILING DATE	PUBLICATION NUMBER	PUBLICATION NUMBER	PUBLICATION DATE	GRANT NUMBER	GRANT DATE	Current Status	Expiry
PAT903483-AR-NP	AR	P090100862	11 Mar 2009	AP070824A1		05 May 2010			Abandoned	10 Mar 2029
PAT903483-AT-EPT	AT	09720520.7	10 Mar 2009	2262506		22 Dec 2010	E666066	07 May 2014	Grant	10 Mar 2029
PAT903483-AU-EPT	AU	2009223649	10 Mar 2009	2262506		22 Dec 2010	2009223649	12 Dec 2013	Grant	10 Mar 2029
PAT903483-BE-EPT	BE	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-BG-EPT	BG	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-BR-EPT	BR	PI0909630-2	10 Mar 2009	PI0909630-2		22 Sep 2015			Allowed	10 Mar 2029
PAT903483-CA-EPT	CA	2717605	10 Mar 2009	2262506		22 Dec 2010	2717605	15 May 2012	Grant	10 Mar 2029
PAT903483-CH-EPT	CH	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-CL-NP	CL	2009-573	11 Mar 2009						Abandoned	10 Mar 2029
PAT903483-CN-EPT	CN	200980107682.3	10 Mar 2009	101959519		26 Jan 2011	200980107682.3	20 Mar 2013	Grant	10 Mar 2029
PAT903483-CZ-EPT	CZ	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-DE-EPT	DE	09720520.7	10 Mar 2009	2262506		22 Dec 2010	602009023878.7	07 May 2014	Grant	10 Mar 2029
PAT903483-DK-EPT	DK	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-EG-EPT	EG	1383/2010	10 Mar 2009	2262506		22 Dec 2010			Abandoned	10 Mar 2029
PAT903483-FE-EPT	EP	09720520.7	10 Mar 2009	EP2262506		22 Dec 2010	EP2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-ES-EPT	ES	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2471122	07 May 2014	Grant	10 Mar 2029
PAT903483-FI-EPT	FI	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-FR-EPT	FR	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-GB-EPT	GB	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-GC-NP	GC	2009/13007	10 Mar 2009				5690	29 May 2017	Abandoned	10 Mar 2029
PAT903483-GR-EPT	GR	09720520.7	10 Mar 2009	EP2262506		22 Dec 2010	3083651	07 May 2014	Grant	10 Mar 2029
PAT903483-HK-FPR	HK	11100290.4	13 Jan 2011	1146464		10 Jun 2011	1146464	15 Aug 2014	Grant	10 Mar 2029
PAT903483-HU-EPT	HU	09720520.7	10 Mar 2009	2262506		22 Dec 2010	E020888	07 May 2014	Grant	10 Mar 2029
PAT903483-IE-EPT	IE	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-IN-EPT	IN	1724MUNNP2010	10 Mar 2009	5212010		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-IT-EPT	IT	09720520.7	10 Mar 2009	2262506		22 Dec 2010	502014902271004	07 May 2014	Grant	10 Mar 2029
PAT903483-JP-EPT	JP	2010-550813	10 Mar 2009	2011-513492		28 Apr 2011	5581227	18 Jul 2014	Grant	10 Mar 2029
PAT903483-KR-EPT	KR	2010-7022609	10 Mar 2009				1555293	17 Sep 2015	Grant	10 Mar 2029
PAT903483-LT-EPT	LT	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-LU-EPT	LU	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-LV-EPT	LV	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-MX-EPT	MX	MXA2010009974	10 Mar 2009			27 Oct 2010	303528	19 Sep 2012	Grant	10 Mar 2029
PAT903483-NL-EPT	NL	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-NO-EPT	NO	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-PL-EPT	PL	1-2010-502060	10 Mar 2009	1-2010-502060		17 Sep 2009	1-2010-502060	20 May 2015	Grant	10 Mar 2029
PAT903483-PT-EPT	PT	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-RO-EPT	RO	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-RU-EPT	RU	2010141542	10 Mar 2009	2010141542		20 Apr 2012	2481842	20 May 2013	Grant	10 Mar 2029
PAT903483-SF-EPT	SE	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-SI-EPT	SI	09720520.7	10 Mar 2009	2262506		22 Dec 2010	2262506	07 May 2014	Grant	10 Mar 2029
PAT903483-SK-EPT	SK	09720520.7	10 Mar 2009	2262506		22 Dec 2010	E16609	07 May 2014	Grant	10 Mar 2029
PAT903483-TW-EPT	TR	09720520.7	10 Mar 2009	2262506		22 Dec 2010	TRP0140666214	07 May 2014	Grant	10 Mar 2029
PAT903483-TW-NP	TW	98107670	10 Mar 2009	200940071		01 Oct 2009	1468165	11 Jan 2015	Grant	10 Mar 2029
PAT903483-US-CNT	US	13/352043	17 Jan 2012	20120115829		10 May 2012			Abandoned	10 Mar 2029
PAT903483-US-DIV	US	13/352009	17 Jan 2012	2012-0116216		10 May 2012	8211880	03 Jul 2012	Grant	10 Mar 2029
PAT903483-US-NP	US	12/401168	10 Mar 2009	2009-0233890		17 Sep 2009	8128960	06 Mar 2012	Grant	17 Dec 2029
PAT903483-US-FSP	US	61/035459	11 Mar 2009						Closed	
PAT903483-UY-NP	UY	31.699	10 Mar 2009						Pending	10 Mar 2029
PAT903483-WO-EPT	WO	PCT/US09/036652	10 Mar 2009	WO/2009/114521		17 Sep 2009			Closed	
PAT903483-ZA-EPT	ZA	2010/05839	10 Mar 2009				2010/05839	26 Oct 2011	Grant	10 Mar 2029